Drug information provided by: Merative, Micromedex®
Elacestrant is used to treat estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR-1 mutated, advanced or metastatic (cancer that has spread) breast cancer that has progressed after receiving endocrine treatment in men or in women who have already stopped menstruating (postmenopausal). Your doctor will test for the presence of the mutation.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.